Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes

Journal of the American College of Cardiology

Volumn 68, Issue 8, 2016, Pages 789-801

  Bansilal, Sameer ^a   Castellano, Jose Maria ^a,b,c   Garrido, Ester ^a,d   Wei, Henry G ^e   Freeman, Allison ^e   Spettell, Claire ^e   Garcia Alonso, Fernando ^d   Lizano, Irene ^d   Arnold, Renee J G ^a   Rajda, Jay ^e   Steinberg, Gregory ^e   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c Hospital Universitario HM Montepríncipe   (Spain)

^d Ferrer Grupo   (Spain)

^e AETNA   (United States)

Author keywords

atherosclerosis; myocardial infarction; secondary prevention

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST CONTROL; DATA BASE; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; CLINICAL TRIAL; COMPLICATION; ECONOMICS; FOLLOW UP; INCIDENCE; INSURANCE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SPAIN; STATISTICS AND NUMERICAL DATA; STROKE; SURVIVAL RATE; TIME FACTOR; TRENDS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSURANCE COVERAGE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; SPAIN; STROKE; SURVIVAL RATE; TIME FACTORS;

EID: 84990184196     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.005     Document Type: Article

References (24)

1. 1 Go, A.S., Mozaffarian, D., Roger, V.L., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292.
2. 2 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
3. 3 Task Force Members, Montalescot, G., Sechtem, U., et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 34 (2013), 2949–3003.
4. 4 Naderi, S.H., Bestwick, J.P., Wald, D.S., Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125 (2012), 882–887.e1.
5. 5 Kumbhani, D.J., Steg, P.G., Cannon, C.P., et al., Reduction of Atherothrombosis for Continued Health Registry Investigators. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 126 (2013), 693–700.e1.
6. 6 Rublee, D.A., Chen, S.Y., Mardekian, J., et al. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Ther 19 (2012), 24–32.
7. 7 Choudhry, N.K., Shrank, W.H., Levin, R.L., et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 15 (2009), 457–464.
8. 8 Rasmussen, J.N., Chong, A., Alter, D.A., Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297 (2007), 177–186.
9. 9 Choudhry, N.K., Setoguchi, S., Levin, R., et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 17 (2008), 1189–1196.
10. 10 Kotseva, K., Wood, D., De Backer, G., et al., EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehab 16 (2009), 121–137.
11. 11 Ho, P.M., Bryson, C.L., Rumsfeld, J.S., Medication adherence: its importance in cardiovascular outcomes. Circulation 119 (2009), 3028–3035.
12. 12 Farkouh, M.E., Boden, W.E., Bittner, V., et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 61 (2013), 1607–1615.
13. 13 Choudhry, N.K., Glynn, R.J., Avorn, J., et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J 167 (2014), 51–58.e5.
14. 14 Newby, L.K., LaPointe, N.M., Chen, A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006), 203–212.
15. 15 Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
16. 16 Gonzalez JM. National health care expenses in the US civilian noninstitutionalized population, 2011. Statistical Brief #425. November 2013. Rockville, MD: Agency for Healthcare Research and Quality. Available at: https://meps.ahrq.gov/data_files/publications/st425/stat425.pdf. Accessed June 14, 2016.
17. 17 Roebuck, M.C., Liberman, J.N., Gemmill-Toyama, M., et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood) 30 (2011), 91–99.
18. 18 Jha, A.K., Aubert, R.E., Yao, J., et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood) 31 (2012), 1836–1846.
19. 19 Sabaté, E., Adherence to Long-Term Therapies: Evidence for Action. 2003, World Health Organization, Geneva, Switzerland.
20. 20 Rogers, A.M., Ramanath, V.S., Grzybowski, M., et al., American College of Cardiology Foundation. The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 154 (2007), 461–469.
21. 21 Choudhry, N.K., Rosenthal, M.B., Milstein, A., Assessing the evidence for value-based insurance design. Health Aff (Millwood) 29 (2010), 1988–1994.
22. 22 Ito, K., Shrank, W.H., Avorn, J., et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res 47 (2012), 2097–2117.
23. 23 Becerra, V., Gracia, A., Desai, K., et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open, 5, 2015, e007111.
24. 24 Grymonpre, R.E., Didur, C.D., Montgomery, P.R., et al. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 32 (1998), 749–754.